Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Change in Inventory: 2020-2025

Historic Change in Inventory for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to $4.1 million.

  • Xeris Biopharma Holdings' Change in Inventory rose 289.79% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.4 million, marking a year-over-year increase of 161.31%. This contributed to the annual value of $8.8 million for FY2024, which is 40.68% down from last year.
  • According to the latest figures from Q3 2025, Xeris Biopharma Holdings' Change in Inventory is $4.1 million, which was down 46.06% from $7.6 million recorded in Q2 2025.
  • Xeris Biopharma Holdings' Change in Inventory's 5-year high stood at $7.6 million during Q2 2025, with a 5-year trough of $148,000 in Q2 2022.
  • Its 3-year average for Change in Inventory is $3.5 million, with a median of $3.1 million in 2024.
  • Its Change in Inventory has fluctuated over the past 5 years, first slumped by 95.49% in 2022, then skyrocketed by 4,922.30% in 2023.
  • Quarterly analysis of 5 years shows Xeris Biopharma Holdings' Change in Inventory stood at $2.3 million in 2021, then soared by 142.08% to $5.5 million in 2022, then tumbled by 74.55% to $1.4 million in 2023, then surged by 123.91% to $3.1 million in 2024, then skyrocketed by 289.79% to $4.1 million in 2025.
  • Its Change in Inventory stands at $4.1 million for Q3 2025, versus $7.6 million for Q2 2025 and $3.6 million for Q1 2025.